Substitute for form 1449A/PTO
INFORMATION DISCLOSURE STATEMENT BY APPLICANTE (Use as many sheets as necessary) NOV 1 8 2004 Sheet 1 of 2

Application Number	10/753,665	
Filing Date January 8, 2004		
First Named Inventor Carson, Dennis		
Group Art Unit	1614	
Examiner Name	Krass, Frederick	

Attorney Docket No: 103.014US3

	US PATENT DOCUMENTS				
Examiner initial.*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate	
FŁ	US- 2002/0042375A1	04/11/2002	Heimbrook, D. C., et al.	06/29/2001	
>	US- 2003/0004142A1	01/02/2003	Prior, C. P., et al.	04/17/2002	
	US- 2003/0004143A1	01/02/2003	Prior, C. P., et al.	04/18/2002	
	US-3,053,255	09/11/1962	Meyer, Friedrich	12/16/1958	
	US-3,710,795	01/16/1973	Higuchi, Takeru, et al.	09/29/1970	
	US-3,843,480	10/22/1974	Dreher, Donald F.	12/04/1967	
	US-3,939,178	02/17/1976	Demerson, Christopher A., et al.	09/15/1972	
	US-3,948,254	04/06/1976	Zaffaroni, Alejandro	08/28/1974	
_/	US-3,948,262	04/06/1976	Zaffaroni, Alejandro	03/10/1975	
	US-3,974,179	08/10/1976	Demerson, Christopher A., et al.	10/10/1974	
	US-3,993,073	11/23/1976	Zaffaroni, Alejandro	03/03/1975	
1	US-4,310,509	01/12/1982	Berglund, Claire A., et al.	07/31/1979	
	US-4,460,562	07/17/1984	Keith, Alec D., et al.	03/30/1983	
- I	US-4,466,953	08/21/1984	Keith, Alec D., et al.	09/30/1982	
	US-4,482,534	11/13/1984	Blank, Izhak	08/18/1983	
	US-4,485,097	11/27/1984	Bell, E.	05/25/1983	
	US-4,505,891	03/19/1985	Ito, Toshio		
100	US-4,533,540	08/06/1985	Blank, Izhak	08/30/1984	
	US-4,542,012	08/17/1985	Dell, John D.	02/11/1983	
	US-4,542,013	09/17/1985	Keith, Alec D., et al.	08/16/1983	
	US-4,560,555	12/24/1985	Snider, Bruno	12/12/1983	
	US-4,585,877	04/29/1986	Demerson, Christopher A., et al.	05/06/1985	
	US-4,597,961	07/01/1986	Etscorn, Frank T.	01/23/1985	
	US-4,608,249	08/26/1986	Otsuka, Saburo	11/02/1982	
	US-4,686,213	08/11/1987	Ferdinandi, Eckhardt S., et al.	08/15/1986	
	US-4,748,252	05/31/1988	Ferdinandi, Eckhardt S., et al.	01/28/1987	
	US-4,806,356	02/21/1989	Shaw, Alec S.	04/03/1987	
	US-4,940,587	07/10/1990	Jenkins, Anthony W., et al.	06/03/1986	
	US-5,599,946	02/04/1997	Vincenzo, Giobbio, et al.	05/30/1995	
	US-5,776,967	07/07/1998	Kreft, Anthony F., et al.	07/07/1997	
	US-5,824,699	10/20/1998	Kreft, Anthony F., et al.	03/16/1998	
	US-5,939,455	08/17/1999	Rephaeli, Ada	03/11/1997 ·	
	US-5,968,974	10/19/1999	Kargman, Stacia, et al.	10/10/1997	
V	US-5,981,592	11/09/1999	Wechter, W. J., et al.	04/09/1998	
V	US-6,160,018	12/12/2000	Wechter, William J., et al.	03/10/1997	
FK	US-6,545,034	04/01/2003	Carson, , et al.	07/23/1999	

Kruss, Frederick **EXAMINER**

DATE CONSIDERED

12-21-04


PTO/SP08A (0-01)
Approved for use through 10/31/2002, OAB 651-0031
LS Priest & Trademant Office: Us. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless a constant a valid vision control number. Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many shaels as necessary)	Application Number	10/753,665	
	Filing Date	January 8, 2004 Carson, Dennis	
	First Named Inventor		
	Group Art Unit	1614	
Ÿ	Examiner Name Krass, Frederick		
Sheet 2 of 2	Attorney Docket No: 1	03.014US3	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T²		
F/2 -	WO-0106990A2	02/01/2001	Carson, Dennis A.			
1	WO-0212188A2	02/14/2002	Carson, Dennis A.			
	WO-9748391A3	12/24/1997	Xiaotao, Quian			
# }	WO-98/40078A1	09/17/1998	Rephaeli, A.			

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Tz			
Ph	1994),2003-2000					
Transgenic Mouse Model for Prostate Cancer", Journal of		LEMAN, EDDY S., et al., "Characterization of the Nuclear Matrix Proteins in a Transgenic Mouse Model for Prostate Cancer", <u>Journal of Cellular Biochemistry</u> , 86, (2002),203-212				
	,	MCCRACKEN, JOHN D., "Antiproliferative Effects of the Enantiomers of Flurbiprofen", Journal of Clinical Pharmacology, (1996),540-545				
PIAZZA, Propertie		PIAZZA, GARY A., "Apoptois Primarily Accounts for the Growth-inhibitory Properties of Sulindac Metabolites and Involves a Mechanism That is Independent of Cyclooxygebase Inhibition, Cell Cycles Arrest, and p53 Induction", Cancer Research, Volume 57, (June 15, 1997),2452-2459				
	•	RILEY, et al., "New Drugs: a six month review", <u>US Pharamacist, Vol. 16,</u> (September 1991),35-64				
		THUN, MICHAEL J., "Aspirin, NSAIDs, and digestive tract cancers", Cancer and Metastasis Reviews 13, Kluwer Academic Publishers., (1994),269-277				
	,	WECHTER, WILLIAM J., "R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer", Inflammopharmacology, Volume 8, No. 2, (2000),189-206				
WECHTER, WILLIAM J., "R-Flurbiprofen Chemoprevention and Treatment of Intestinal Adenomas in the APC min/+ Mouse Model: Implications for Prophylaxis and Treatment of Colon Cancer", Cancer Research, Volume 57,						
#k		Number 19, (October 1, 1997),4316-4324. WECHTER, WILLIAM J., "Rac-Flurbiprofen Is More Ulcerogenic Than Its (S)-				
14		Enantiomer", Chirality, Volume 5, Number 7, (1993),492-494	Щ.			

EXAMINER	Krass,	Frederek	DATE CONSIDERED 12-21-04	, .



Approved for use through 10/31/2002, OMB 651-0031
US Paint & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449APTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	Unknown (6) 753,665	
	Filing Date	Even Date Herewith 1/8/04	
	First Named Inventor	Carson, Dennis	
	Group Art Unit	Unknown /6/4	
	Examiner Name	Krass, Frederick	
Sheet 1 of 4	Attorney Docket No: 1	103.014US3	

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
FK	US-3,843,681	10/22/1974	Demerson, C. A., et al.	260	326.14 R	06/01/1971
7	US-4,337,760	07/06/1982	Rubin, D.	128	1R	10/31/1979
	US-5,561,151	10/01/1996	Young, J. W., et al.	514	411	01/04/1995
J	US-5,811,558	09/22/1998	Adger, B. M., et al.	548	427	04/11/1995
4k	US-5,955,504	09/21/1999	Wechter, William J., et al.	514	568	03/13/1995

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T²	
FK	DE-2226340	03/15/1973	Demerson, Christopher A., et al.	C07 D	27/56		
1	EP-0289262	11/02/1986	Venuti, M. C., et al.	C07 C	93/00		
	WO-00/02555	01/20/2000	Nardella, Francis A., et al.	A61K	31/40		
	WO-00/13410	03/09/2000	Monroe, D. A.	H04 N	5/76		
V,	WO-96/28148	09/19/1996	Wechter, William J., et al.	A61K	31/19		
	WO-98/09603	03/12/1998	Wechter, William J., et al.	A61K			
th	WO-98/18490	05/07/1998	Clynes, M. M.	A61K	45/06		

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1,
FK		The Merck Index, Eleventh Edition, Budavari, S., et al., (eds.), Merck & Co., Inc., Rahway, N.J., Entry No. 3831 "Etodolac",(1989),p. 608	
		In: Remington's Pharmaceutical Sciences, Eighteenth Edition, Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),pp. 1115-1121	
		ABRAMSON, S. B., et al., "The Mechanisms of Action of Nonsteroidal Antiinflammatory Drugs", Arthritis & Rheumatism, 32 (1), (Jan. 1989),pp. 1-9	
		ALEXANIAN, R., et al., "The Treatment of Multiple Myeloma", The New England Journal of Medicine, 330 (7), (Feb. 17, 1994),pp. 484-489	
	7	BARLOGIE, B, et al., "Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.", Blood, 72, (1988),2015-2019	
V		BATAILLE, R, et al., "Multiple Myeloma", New England Journal of Medicine, 336, (1997),1657-1664	
Fk		BECKER-SCHARFENKAMP, U., et al., "Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography", Journal of Chromatography, 621 (2), (Nov. 24, 1993),pp. 199-	

EXAMINER	Krass, 7	Frederick	DATE CONSIDERED	12-21-04
				- 0

PTO/SB/084(10-01)
Approved for use through 10/31/2002. ONB 551-0031
Peters & Tirstmark Office: U.S. DEPARTMENT OF COMMERCE
Information unless it commerces a valid FALE market

Substitute for form 1449APTO	Under the Peperwork Reduction Act of 1995, no persons are recipred to respond to a consection of information unless it contains a Year Conduction for the Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as nocessary)	Application Number	Unknown 10 753-665	
	Filing Date	Even Date Herewith 1/8/04	
	First Named Inventor	Carson, Dennis	
	Group Art Unit	Unknown /6/4	
	Examiner Name	Krass, Frederick	
Sheet 2 of 4	Attorney Docket No: 1	103.014US3	

	OTHER	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*.
BK		207	
1	-	BELLOSILLO, B., et al., "Aspirin and Salicylate Induce Apoptosis and Activation	
		of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells", Blood, 92 (4),	ŀ
		(Aug. 15, 1998),pp. 1406-1414	1
		BERENDES, U., et al., "Simultaneous Determination of the Phase II Metabolites	}
		of the Non Steriodal Anti-inflammatory Drug Etodolac in Human Urine",	
		Enantiomer, 1, Abstract Only, Chemical Abstracts, Abstract No.	
		126:207064q,(1996),415-422	1
		BRENNA, E., et al., "New Enzymatic and Chemical Approaches to Enantiopure	
1 1 1		Etodolac", Tetrahedron, 53, (1997), 17769-17780	J
		BROCKS, D. R., et al., "Etodolac Clinical Pharmacokinetics", Clinical	
		Pharmacokinetics, 26 (4), (1994),pp. 259-274	
		CARSON, D. A., et al., "Oral Antilymphocyte Activity and Induction of Apoptosis	<u> </u>
		by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine", Proc. Natl. Acad. Sci. USA, 89	1
1 1		(7), (Apr. 1992),pp. 2970-2974	
		CHINETTI, G., et al., "Activation of Proliferator-activated Receptors alpha and Y	<u> </u>
		Induces Apoptosis of Human Monocyte-derived Macrophages", The Journal of	
		Biological Chemistry, 273 (40), (Oct. 2, 1998),pp. 25573-25580	
		CUNNINGHAM, D , et al., "High-dose Melphalan for Multiple Myeloma: Long-	
		term Follow-up Data", Journal of Clinical Oncology, 12, (1994),764-768	
		DEMERSON, C. A., et al., "Etodolic Acid and Related Compounds. Chemistry	
		and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-	
		Tetrahydropyrano[3,4-b]indole-1-acetic Acids", Journal of Medicinal Chemistry,	
	•	19 (3), (1976),pp. 391-395	
		DEMERSON, C. A., et al., "Resolution of Etodolac and Antiinflammatory and	-
		Prostaglandin Synthetase Inhibiting Properties of the Enantiomers", J. Med.	
		Chem., 26 (12), (Dec. 1983),pp. 1778-1780	ļ
		DRACHENBERG, D. E., "Treatment of Prostate Cancer: Watchful Waiting,	-
		Radical Prostatectomy, and Cryoablation", <u>Seminars in Surgical Oncology</u> , 18	1
		(1), (Jan/Feb. 2000),pp. 37-44	
		DUFFY, C. P., et al., "Enhancement of Chemotherapeutic Drug Toxicity to	
		Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory	
		Drugs (NSAIDs)", European Journal of Cancer, 34 (8), (July 1998),pp. 1250-	
		1259	
		HAHNFELD, L. E., et al., "Prostate Cancer", The Medical Clinics of North	
1		America - The Aging Male Patient, 83 (5), (Sept. 1999),pp.1231-1245	100
		HAROUSSEAU, J. L., et al., "Double-Intensive Therapy in High-Risk Multiple	
1 1 1		Myeloma", <u>Blood, 79 (11),</u> (June 1, 1992),pp. 2827-2833	
7,		KRAJEWSKI, S., et al., "Detection of Multiple Antigens on Western Blots",	
V		Analytical Biochemistry, 236 (2), Article No. 0160,(May 1996),pp. 221-228	
The Wall		LANDIS, S. H., et al., "Cancer Statistics, 1998", CA Cancer J. Clin., 48 (1),	
<u> </u>			LJ

EXAMINER Krass, Fraderick DATE CONSIDERED 12-21-04

PTC/SB/06A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
Patent A Tradement Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449APTO	Under the Paperwork Reduction Act of 1995, no parsons are required to respond to a collection of information unless it contains a valid DMB control number. Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	Unknown 10/753 665	
(Use as many sheets as necessary)	Filing Date	Even Date Herewith 1//8/04	
	First Named Inventor	Carson, Dennis	
	Group Art Unit	Unknown /6/4	
	Examiner Name	Krass, Frederick	
Sheet 3 of 4	Attorney Docket No: 103.014US3		

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
#1		(1998),pp. 6-29	
		LEE, D. H., "Proteasome Inhibitors: Valuable New Tools For Cell Biologists",	
		Trends in Cell Biology, 8, (October 1998),pp. 397-403	1
	*	LEHMANN, J. M., et al., "Peroxisome Proliferator-activated Receptors alpha and	
1 \ 1		Y Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory	1
		Drugs", The Journal of Biological Chemistry, 272 (6), (Feb. 7, 1997),pp. 3406-	
		3410	
		LEONI, L. M., et al., "Induction of an Apoptotic Program in Cell-Free Extracts by	Ĭ .
	`	2-Chloro-2'-deoxyadenosine 5'-triphosphate and Cytochrome C", PNAS, USA,	
		95 (16), (Aug. 4, 1998),pp. 9567-9571	
		LOCHMULLER, C. H., et al., "Chromatographic Resolution of Enantiomers	
]]]		Selective Review", Journal of Chromatography, 113 (3), (Oct. 22, 1975),pp. 283-	l
		302	
		MARTEL, R. R., et al., "Anti-inflammatory and Analgesic Properties of Etodolic	
		Acid in Rats", Canadian Journal of Physiology and Pharmacology, 54 (3), (June	l
		1976),pp. 245-248	
		MOONEY, P. T., et al., "Cell Pathways' Exisulind 'Aptosyn' Demonstrates	-
]		Potential to Delay Hormone Therapy in Post-Prostatectomy Men at Risk of	1
]] [Prostate Cancer Recurrence",	
		http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html, (May 2000),3 p.	<u> </u>
		NARDELLA, FRANCIS A., et al., "Enhanced Clearance of Leukemic	
		Lymphocytes in B Cell Chronic Lymphocytic Leukemia (CLL) with Etodolac",	l
		Arthritis & Rheumatism, 42 (9) Supplement, Abstract No. 41, (Sept. 1999),p.	
		S56	
		RICOTE, M., et al., "The Peroxisome Proliferator-Activated Receptor-Y is a	
		Negative Regulator of Macrophage Activation", Nature, 391, (Jan. 1, 1998),pp.	!
		79-82	
!!!		RIEDEL, D. A., et al., "The Epidemiology of Multiple Myeloma",	
1 .		Hematology/Oncology Clinics of North America, Multiple Myeloma, 6 (2), (April	
		1992),pp. 225-247	
		ROYALL, J. A., et al., "Evaluation of 2',7'-Dichlorofluorescin and	1
] []		Dihydrorhodamine 123 as Fluorescent Probes for Intracellular H2O2 in Cultured	İ
		Endothelial Cells", Archives of Biochemistry and Biophysics, 302 (2), (May 1,	
 		1993),pp. 348-355	ļ
		SHIFF, S. J., et al., "Nonsteroidal Antiinflammatory Drugs Inhibit the Proliferation	
		of Colon Adenocarcinoma Cells: Effects on Cell Cycle and Apoptosis",	
 		Experimental Cell Research, 222, Article No. 0023,(1996),pp. 179-188	
\ /	•	TANG, D. G., et al., "Target to Apoptosis: A Hopeful Weapon for Prostate	
<u> </u>	·	Cancer", The Prostate, (1997),pp. 284-293	
#k		VAN BREEMEN, R. B., et al., "Characterization of Oxygen-Linked Glucuronides	
		by Laser Desorption Mass Spectrometry", Biomed. Mass Spectrom., 11, Abstract	

EXAMINER	Krass.	Frederick	DATE CONSIDERED	12-21-04
----------	--------	-----------	-----------------	----------

Substitute for form 1449A/PTO	Complete if Known	required to respond to a collection of information unless it borrains a valid Onle control number.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	Unknown 101753.665
(Use as many sheels as necessary)	Filing Date	Even Date Herewith 1/18/04
9	First Named Inventor	Carson, Dennis
-	Group Art Unit	Unknown 1614
	Examiner Name	Krass, Frederick
Sheet 4 of 4	Attorney Docket No: 1	03.014US3

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
PK		Only, Chemical Abstracts, Abstract No. 101:106777c,(1984),278-283	
146		VENUTI, M. C., et al., "Synthesis and Biological Evaluation of omega-(N,N,N-trialkylammonium)alkyl Esters and Thioesters of Carboxylic Acid Nonsteroidal Antiinflammatory Agents", Pharm. Res. , Abstract Only , Chemical Abstracts, Abstract No. 112:111681y, (1989), 867-873	
	ž	WANG, X., et al., "Antipoptotic Action of 1,25-Dihydroxyvitamin D3 Is Associated with Increased Mitochondrial MCL-1 and RAF-1 Proteins and Reduced Release of Cytochrome c", <u>Experimental Cell Research</u> , 235 (1), Article No. EX973667,(1997),pp. 210-217	
		WECHTER, W. J., et al., "E-7869 (R-Flurbiprofen) Inhibits Progression of Prostate Cancer in the TRAMP Mouse", Cancer Research, 60, (April 15, 2000),pp. 2203-2208	
		WEISS, H. A., et al., "Aspirin, Non-Steroidal Anti-Inflammatory Drugs and Protection from Colorectal Cancer: a Review of the Epidemiological Evidence", Scandinavian Journal of Gastroenterology, 31 (Suppl. 220), (1996),pp. 137-141	
Pk.		WILEN, S. H., et al., "Strategies In Optical Resolutions", <u>Tetrahedron, 33 (21)</u> , Tetrahedron Report Number 38,(1977),pp. 2725-2736	

Krass, Frederick **EXAMINER**

DATE CONSIDERED

12-21-08